Boston Scientific's Upside With Cardiology Devices Drives Momentum
Portfolio Pulse from Vandana Singh
Mizuho Securities has raised the price target for Boston Scientific Corporation (NYSE: BSX) from $85 to $90, citing strong growth in the cardiology segment driven by products like Farapulse and Watchman FLX. The company is expected to maintain double-digit growth, with potential for a $115 bull case price target.
May 15, 2024 | 7:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho Securities has raised the price target for Boston Scientific Corporation (NYSE: BSX) from $85 to $90, driven by strong growth in the cardiology segment. The company is expected to maintain double-digit growth, with potential for a $115 bull case price target.
The price target increase is based on strong growth projections in the cardiology segment, particularly from products like Farapulse and Watchman FLX. This is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100